Huanzhang Advances TFA-01 Registration PreparationsTFA Chief Technology Officer Reviews Clinical Study Procedures in Shanghai
Injectable nanoformulation developed in Taiwan delivered to Shanghai Paitesai for canine osteoarthritis studies under China’s new veterinary drug registration requirements
XIAMEN, October 20, 2026 — Xiamen Huanzhang Biopharmaceutical Technology Co., Ltd. (Huanzhang) is advancing preparations for TFA-01 veterinary drug registration in China. TFA Chief Technology Officer Vincent Liu recently visited Shanghai Paitesai to review the study environment and animal-care arrangements and confirm planned procedures for the canine osteoarthritis study with the clinical team.
The TFA-01 injectable nanoformulation developed by Taiwan’s Institute of Animal Vaccine Technology and collaborating research teams has been delivered to Shanghai Paitesai for subsequent canine osteoarthritis clinical trials. The delivery and on-site coordination further connect formulation development in Taiwan with clinical study execution in Shanghai.
The TFA-01 injectable nanoformulation, developed by Taiwan’s Institute of Animal Vaccine Technology and collaborating research teams, has been delivered to Shanghai Paitesai for subsequent canine osteoarthritis clinical trials.TFA Chief Technology Officer Vincent Liu visits Shanghai Paitesai to review the study environment and operational arrangements and confirm subsequent study procedures with the clinical team.
Confirming Veterinary GCP Procedures for Registration-Supporting Clinical Studies
The on-site coordination focused on clinical research needed for new veterinary drug registration. The teams confirmed that subsequent trials are to be conducted in accordance with China’s Good Clinical Practice for Veterinary Drugs (Veterinary GCP) and relevant registration requirements. Dosing, observations and assessments, source records and study reports will be managed under these standards to establish complete, traceable research data.
Building Registration Data Through Standardized Studies
TFA-01 is an investigational drug candidate based on Antcin A, with canine osteoarthritis as its lead indication. As the exclusive entity responsible for TFA-01 development and commercialization in China, Huanzhang will continue coordinating the TFA development team and Shanghai Paitesai. Delivery of study supplies, on-site confirmation of procedures and subsequent standardized studies will support the collection of efficacy and safety data for new veterinary drug registration preparations in China.